Duchenne Muscular Dystrophy Drugs Market Size & Competitors

The Duchenne Muscular Dystrophy Drugs Market is experiencing transformation as clinical breakthroughs, innovative delivery platforms, and shifting regulatory standards reshape the outlook for biopharmaceutical stakeholders. Senior decision-makers must anticipate changing care models and adapt to an increasingly complex therapeutic environment.

Market Snapshot: Duchenne Muscular Dystrophy Drugs Market

The Duchenne Muscular Dystrophy Drugs Market is expanding, driven by sustained clinical innovation and increasing entry of genetic therapies. Recent years have seen robust gains in market size, supported by a compound annual growth rate (CAGR) of 9.31%. This favourable climate results from continued investment in resilient supply chains, the rollout of next-generation therapeutics, and evolving treatment guidelines that elevate standards of care for Duchenne patients. These dynamics are prompting industry leaders to optimize product portfolios and respond to accelerated regulatory timelines.

Scope & Segmentation

Drug Classes: The market is segmented across exon skipping therapies, multiple gene therapy approaches—including AAV-based, nonviral methods, and serotype 6/9 distinctions—and established steroid therapies, reflecting high pipeline diversity.
Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies all play significant roles in enabling access, shaping reimbursement pathways, and supporting treatment continuity.
End-User Settings: Home healthcare, hospitals, and specialty clinics are focal points for therapy administration; the increasing shift toward home-based care requires tailored support models and changes in supply strategies.
Formulation Types: Capsules, injectables, and oral tablets offer distinct administration benefits, influencing patient adherence and preferences.
Routes of Administration: Intramuscular, intravenous, and oral delivery options align with advances in drug development.
Regions Covered: Americas, Europe, Middle East & Africa, and Asia-Pacific drive regional differentiation in access, regulatory navigation, and commercialization approaches.

Each market segment shapes operational planning—from distribution network design to health system engagement strategies. Gene therapy innovation, expansion of delivery infrastructure, and evolving regulatory processes demand precise, region-specific approaches. Aligning portfolio development and launch sequencing with distinct segment requirements is essential for maximizing patient reach and operational efficiency.

Key Takeaways

Ongoing adoption of disease-modifying therapies is redefining care standards and shifting commercial focus toward durability and real-world impact.
Collaboration across clinical, payer, and patient advocacy stakeholders is essential for optimizing trial recruitment strategies and refining critical clinical endpoints.
Increased complexity in therapy manufacturing and delivery underscores the need for robust operational agility and reliable supply partnerships to ensure longevity and resilience.
Payer engagement and rigorous evidence generation—including use of real-world data—are central to market access and reinforcing product value for stakeholders.
Regional differences in regulatory environments and health system infrastructures require customized access strategies, targeted investment in local capacity, and thoughtful commercialization planning.

Tariff Impact

Recent adjustments to tariff policies in the United States are contributing additional complexity to the Duchenne supply chain. Costs associated with imported materials, manufacturing inputs, and finished drugs have increased, prompting stakeholders to pursue nearshoring, multi-sourcing, and greater investment in domestic manufacturing. These developments influence decisions on site selection, logistics optimization, and pricing strategy. Strategic moves to strengthen manufacturing resiliency will help maintain uninterrupted patient access and competitive market positioning.

Methodology & Data Sources

This analysis is informed by in-depth primary interviews with clinical leaders, supply chain professionals, payer representatives, and patient advocates. The research incorporates synthesis of clinical trial registries, regulatory documentation, company filings, and peer-reviewed literature. Analytical methods include cross-validation, supply risk assessment, and review of regulatory pathways to deliver actionable insights tailored for industry leaders.

Why This Report Matters

Equips executives to identify potential shifts in therapeutic innovation and respond to evolving supply and regulatory risks in the Duchenne Muscular Dystrophy Drugs Market.
Supports informed strategic planning through a clear breakdown of segmentation, operational challenges, and the impact of policy adjustments within the market landscape.
Facilitates confident portfolio and partnership decisions—clarifying the connections between emerging trends, regulatory demands, and stakeholder expectations.

Conclusion

Success in the Duchenne Muscular Dystrophy Drugs Market requires agile operational strategies, cross-functional collaboration, and continuous stakeholder engagement. Senior leaders equipped to address scientific and regulatory developments will maintain strong positions in delivering innovative therapies and improving patient outcomes.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Duchenne Muscular Dystrophy Drugs Market, by Drug Class

8.1. Exon Skipping
8.2. Gene Therapy
8.2.1. Aav Based
8.2.1.1. Serotype 6
8.2.1.2. Serotype 9
8.2.2. Nonviral
8.3. Steroid Therapy

9. Duchenne Muscular Dystrophy Drugs Market, by Form

9.1. Capsule
9.2. Injectable
9.3. Oral Tablet

10. Duchenne Muscular Dystrophy Drugs Market, by Route Of Administration

10.1. Intramuscular
10.2. Intravenous
10.3. Oral

11. Duchenne Muscular Dystrophy Drugs Market, by Distribution Channel

11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies

12. Duchenne Muscular Dystrophy Drugs Market, by End User

12.1. Home Healthcare Settings
12.2. Hospitals
12.3. Specialty Clinics

13. Duchenne Muscular Dystrophy Drugs Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Duchenne Muscular Dystrophy Drugs Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Duchenne Muscular Dystrophy Drugs Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Duchenne Muscular Dystrophy Drugs Market
17. China Duchenne Muscular Dystrophy Drugs Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Anuh Pharma Limited
18.6. Arlak Biotech Pvt.Ltd.
18.7. Aurigene Pharmaceutical Services Ltd.
18.8. Bayer Pharmaceutical
18.9. Cipla Inc.
18.10. Enomark
18.11. Glasier Wellness, Inc.
18.12. GlaxoSmithKline PLC
18.13. Johnson & Johnson Services, Inc.
18.14. Leo Pharma
18.15. Lifecare Neuro Products Limited
18.16. Mankind Pharma Ltd.
18.17. Merck & Co., Inc.,
18.18. MODASA Pharmaceuticals Pvt. Ltd.
18.19. Novartis AG
18.20. Pfizer Inc.
18.21. QndQ Derma
18.22. RayBiotech, Inc.
18.23. Ronyd Healthcare Pvt Ltd.
18.24. Sarepta Therapeutics, Inc.
18.25. Sumitomo Corporation
18.26. Texas Pharmaceuticals Pvt. Ltd.
18.27. Wellona Pharma
18.28. Zuventus Healthcare Ltd.

List of Figures

FIGURE 1. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 99. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 101. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 102. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 103. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 104. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 106. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 117. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 118. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 119. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 120. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 121. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 134. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 135. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 136. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 137. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 138. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 142. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 143. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 144. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 145. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 146. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 153. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 158. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 159. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 160. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 161. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 162. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 166. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 167. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 168. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 169. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 170. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 174. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 175. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 176. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 177. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 182. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 183. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 184. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 185. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 186. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 187. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 188. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 190. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 191. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 192. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
TABLE 193. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 194. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 195. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 196. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Duchenne Muscular Dystrophy Drugs market report include:

Anuh Pharma Limited
Arlak Biotech Pvt.Ltd.
Aurigene Pharmaceutical Services Ltd.
Bayer Pharmaceutical
Cipla Inc.
Enomark
Glasier Wellness, Inc.
GlaxoSmithKline PLC
Johnson & Johnson Services, Inc.
Leo Pharma
Lifecare Neuro Products Limited
Mankind Pharma Ltd.
Merck & Co., Inc.,
MODASA Pharmaceuticals Pvt. Ltd.
Novartis AG
Pfizer Inc.
QndQ Derma
RayBiotech, Inc.
Ronyd Healthcare Pvt Ltd.
Sarepta Therapeutics, Inc.
Sumitomo Corporation
Texas Pharmaceuticals Pvt. Ltd.
Wellona Pharma
Zuventus Healthcare Ltd.

Table Information

Report Attribute	Details
No. of Pages	180
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 2.02 Billion
Forecasted Market Value ( USD ) by 2032	$ 3.46 Billion
Compound Annual Growth Rate	9.3%
Regions Covered	Global
No. of Companies Mentioned	25

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3458EUR$3,939USD£3,008GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3730EUR$4,249USD£3,245GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5055EUR$5,759USD£4,398GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6117EUR$6,969USD£5,322GBP

Duchenne Muscular Dystrophy Drugs Market - Global Forecast 2026-2032

Market Snapshot: Duchenne Muscular Dystrophy Drugs Market

Scope & Segmentation

Key Takeaways

Tariff Impact

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Market Snapshot: Duchenne Muscular Dystrophy Drugs Market

Scope & Segmentation

Key Takeaways

Tariff Impact

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Duchenne Muscular Dystrophy Drugs - Global Strategic Business Report

Duchenne Muscular Dystrophy Drugs Global Market Report 2025

Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast 2025-2034

Duchenne Muscular Dystrophy Market Report 2025

Duchenne Muscular Dystrophy - Pipeline Insight, 2025

About the Duchenne Muscular Dystrophy Drug Market